Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07246187 · ClinicalTrials.gov registry record · Phase 3
Comparing Haloperidol to Olanzapine in the Treatment of Suspected Cannabinoid Hyperemesis in the Emergency Department
A Phase 3 study of Cannabinoid Hyperemesis Syndrome, sponsored by Mercy Bon Secours Saint Vincent Medical Center.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 114
- Enrollment target
- 1
- Study location
NCT07246187: Recruiting Phase 3 study of Cannabinoid Hyperemesis Syndrome, sponsored by Mercy Bon Secours Saint Vincent Medical Center.
NCT07246187 is a Phase 3 study of Cannabinoid Hyperemesis Syndrome that is actively recruiting participants, run by Mercy Bon Secours Saint Vincent Medical Center. The registered enrollment target is 114 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (85% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07246187, a Phase 3 study of Cannabinoid Hyperemesis Syndrome, is actively recruiting participants, sponsored by Mercy Bon Secours Saint Vincent Medical Center.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 114 participants
- Enrollment target
- 1
- Study location
Study Summary
The aim of the study is to identify which medication (haloperidol or olanzapine) is most effective in treating nausea and abdominal pain associated with cannabinoid hyperemesis using a 10-point visual analog scale with intervals of 0.5.
Primary Outcome
nausea symptoms on a scale of 0-10 with 0 being no nausea and 10 being the worst nausea
Conditions Studied
Interventions
- DRUG Olanzapine 10 milligram
- DRUG Haloperidol
Study Locations (1)
Ohio
- Mercy Saint Vincent Medical Center - Toledo
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 114 participants |
| Start Date | 2025-11-06 |
| Est. Completion | 2026-11 |
| Phase | Phase 3 |
What NCT07246187 shows while recruiting
NCT07246187 is an interventional study that assigns participants to a tested intervention. The registered 114 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (85% lower).
The record links to 1 condition, with Cannabinoid Hyperemesis Syndrome appearing as the primary indexed condition, and to 2 interventions - of which Olanzapine 10 milligram is the first listed.
NCT07246187 reports a single indexed study location in Ohio.
Frequently Asked Questions
What is clinical trial NCT07246187 about?
NCT07246187 is a clinical study titled "Comparing Haloperidol to Olanzapine in the Treatment of Suspected Cannabinoid Hyperemesis in the Emergency Department". The aim of the study is to identify which medication (haloperidol or olanzapine) is most effective in treating nausea and abdominal pain associated with cannabinoid hyperemesis using a 10-point visual analog scale with intervals of 0.5.
What is the current status of trial NCT07246187?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 114 participants. The study started on 2025-11-06. Estimated completion is 2026-11.
What conditions does trial NCT07246187 study?
This clinical trial studies the following conditions: Cannabinoid Hyperemesis Syndrome.
What interventions are being tested in trial NCT07246187?
The interventions under investigation include: Olanzapine 10 milligram (DRUG), Haloperidol (DRUG).
Who is sponsoring clinical trial NCT07246187?
This trial is sponsored by Mercy Bon Secours Saint Vincent Medical Center, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07246187 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07246187's enrollment target sits among peer trials
114 1649th of 2000 higher than 350 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04522791 · 114 participants · Phase 2
Breathing, Relaxation, Attention Training, & Health in Older Adults (BREATHE)
- NCT04875052 · 114 participants · NA
Vibration and Post-traumatic Osteoarthritis Risk Following ACL Injury
- NCT05100342 · 114 participants
Prospective Validation of a Points Score System Predicting 30-day Survival
- NCT05224089 · 114 participants · Phase 4
Bilateral TAP and RS Blocks Using Liposomal Bupivacaine/Bupivacaine vs. Regular Bupivacaine in Laparoscopic Colectomy
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI